AU2022203265A1 — Hydrazide containing nuclear transport modulators and uses thereof
Assigned to Karyopharm Therapeutics Inc · Expires 2022-06-02 · 4y expired
What this patent protects
OF THE INVENTION The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: N--N pNH N - O N-R2 F 3C N> R R3 CF 3 or a pharmaceutically acceptable salt thereof, wherei…
USPTO Abstract
OF THE INVENTION The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: N--N pNH N - O N-R2 F 3C N> R R3 CF 3 or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.